Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUPUS: Neoadjuvant intra-arterial [177Lu]Lu-PSMA-617 before radical prostatectomy in high-risk localized or locally advanced prostate cancer
2022-500838-28-00Phase 2Authorised
- Sponsor
- Universitätsmedizin Essen
- Start
- Nov 2023
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lutetium lu 177 vipivotide tetraxetan in prostate cancer (PCa), sponsored by Universitätsmedizin Essen. Primary endpoints: Adverse Events related to intra-arterial [177Lu]Lu-PSMA-617 therapy and Delay of scheduled surgery due to AEs. Planned start Nov 2023; status: authorised.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2022-500838-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500838-28-00.